- Home
- DXLG vs ADVM Comparison
DXLG vs ADVM Comparison
Compare DXLG & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- ADVM
- Stock Information
- Founded
- DXLG 1976
- ADVM 2006
- Country
- DXLG United States
- ADVM United States
- Employees
- DXLG N/A
- ADVM N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXLG Consumer Discretionary
- ADVM Health Care
- Exchange
- DXLG Nasdaq
- ADVM Nasdaq
- Market Cap
- DXLG 156.7M
- ADVM 161.4M
- IPO Year
- DXLG 1987
- ADVM 2014
- Fundamental
- Price
- DXLG $2.84
- ADVM $6.86
- Analyst Decision
- DXLG Buy
- ADVM Strong Buy
- Analyst Count
- DXLG 2
- ADVM 6
- Target Price
- DXLG $3.50
- ADVM $27.83
- AVG Volume (30 Days)
- DXLG 224.3K
- ADVM 159.8K
- Earning Date
- DXLG 11-22-2024
- ADVM 11-04-2024
- Dividend Yield
- DXLG N/A
- ADVM N/A
- EPS Growth
- DXLG N/A
- ADVM N/A
- EPS
- DXLG 0.25
- ADVM N/A
- Revenue
- DXLG $496,639,000.00
- ADVM $1,000,000.00
- Revenue This Year
- DXLG N/A
- ADVM N/A
- Revenue Next Year
- DXLG $6.38
- ADVM $1,294.35
- P/E Ratio
- DXLG $11.47
- ADVM N/A
- Revenue Growth
- DXLG N/A
- ADVM N/A
- 52 Week Low
- DXLG $2.19
- ADVM $6.38
- 52 Week High
- DXLG $4.76
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- DXLG 48.96
- ADVM 35.85
- Support Level
- DXLG $2.91
- ADVM $7.26
- Resistance Level
- DXLG $3.06
- ADVM $8.05
- Average True Range (ATR)
- DXLG 0.13
- ADVM 0.40
- MACD
- DXLG 0.01
- ADVM -0.11
- Stochastic Oscillator
- DXLG 42.50
- ADVM 2.94
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.